Introduction: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subtype of ALL, accounting for 10–25% of cases, with a predominance in children and adolescents. It is associated with higher rates of induction failure and early relapse compared to B-cell ALL (B-ALL). In Brazil, data on T-ALL remain scarce, particularly in regions with low population density and limited access to pediatric oncology services, such as the Northern region. This gap hampers a comprehensive understanding of its epidemiology and may exacerbate disparities in clinical outcomes. Objectives: This study aimed to characterize the clinical and epidemiological profile of pediatric patients with T-ALL treated at a regional pediatric oncology referral center. Methods: This was a cross-sectional, retrospective, and quantitative study, approved by the Research Ethics Committee of the Federal University of Pará (approval number 119.649). Medical records of 137 ALL patients treated at the Octavio Lobo Pediatric Oncology Hospital (Belém, Pará, Brazil) between 2015 and 2018 were analyzed according to the BFM-2002 and St. Jude Children’s Research Hospital (SJCRH) protocols. Statistical analysis was conducted using R software (version 4.3.3). Results: Among the patients, 123 (89.8%) had B-ALL and 14 (10.2%) had T-ALL. In the T-ALL group, the mean age was 5.6 ± 3.9 years, with a predominance of males (12 patients; 85.7%). The mean initial leukocyte count was 108,024/mm³, hemoglobin level was 8.9 g/dL, and platelet count was 58,144/mm³. The most frequent treatment-related toxicities were infectious (11 patients; 78.6%), hematological (9 patients; 64.3%), gastrointestinal (8 patients; 57.1%), and central nervous system (5 patients; 35.7%). The mortality rate in this group was 21.4% (3 patients), and the relapse rate reached 28.6% (4 patients). Conclusion: The findings reinforce the clinically aggressive nature of T-ALL and highlight the need to improve early diagnosis and access to specialized care in regions with heightened healthcare vulnerability. Despite the limitation of a small sample size, the findings contribute valuable insights into regional disparities in pediatric oncology care.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
